Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer By Ogkologos - July 15, 2025 695 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POD1UM-303/InterAACT-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Tarlatamab April 17, 2026 For Women with Breast Cancer, Regular Exercise May Improve Survival May 15, 2020 Cauliflower Rice August 28, 2020 Withdrawal of Application to Change the EU Marketing Authorisation for Cervarix November 25, 2021 Load more HOT NEWS Clinical Trials in Genitourinary Cancers: MAGNITUDE, PROOF 302, and CYTOSHRINK First Mature Estimation of Median OS for Selpercatinib in Patients with... The Risk of irAEs After Immune Checkpoint Inhibitor Therapy May Not... Adding Blinatumomab to Consolidation Chemotherapy Improves OS in Adult Patients in...
